Introduction
Vascular endothelial growth factor C (VEGF-C) belongs to the platelet-derived growth factor family. It binds to Flt4/VEGF receptor 3 (VEGFR3), a receptor tyrosine kinase that is expressed in lymphatic endothelial cells (Joukov et al., 1996) , certain non-endothelial cells such as osteoblasts (Orlandini et al., 2006) and many cancer cell types (Strizzi et al., 2001; Jackson et al., 2002; Su et al., 2006; Timoshenko et al., 2007) . With significantly lower affinity VEGF-C interacts with VEGFR2, which is primarily involved in the induction of hemangiogenesis (Skobe et al., 1999; Shibuya and Claesson-Welsh, 2006) and coreceptors, including the neuropilin-2 expressed on veins and lymphatic vessels (Karkkainen et al., 2001; Karpanen et al., 2006; Xu et al., 2010) . The major physiological function of VEGF-C is generally accepted to be the induction of lymphangiogenesis (reviewed by Bahram and ClaessonWelsh (2010) ; Tammela and Alitalo (2010) ).
Accumulating data indicate that VEGF-C is involved in the progression of several types of malignant tumors including most common ones such as non-small cell lung cancer, colorectal cancer, breast carcinoma, and so on (Arinaga et al., 2003; Su et al., 2006; Gu et al., 2008; Miyazaki et al., 2008; Yamashita et al., 2010) , that allowed proposing VEGF-C as a prospective cancer drug target. Initially, it was thought that VEGF-C synthesized in cancer cells promotes metastasis mainly through induction of lymphangionenesis in tumor tissues and sentinel lymph nodes that facilitated the spread of cancer cells via the lymphatic vessels (Mandriota et al., 2001; He et al., 2002; Hoshida et al., 2006) . However, several recent studies reported that autocrine regulation of cancer cells migration via VEGF-C/VEGFRs is an important inducer of tumor cell proliferation, invasion and metastasis (Timoshenko et al., 2007; Kodama et al., 2008; Su et al., 2006 Su et al., , 2008 Chen et al., 2010) . This stimulation of cancer cell motility is partly mediated by activation of VEGFR3-Src-p38MAPK-C/EBP-contactin-1 pathway (Su et al., 2006) ; however, other possible mechanisms of induction of cell locomotion by VEGF-C remain largely unknown.
To assess the effect of inhibition of VEGF-C synthesis in cancer cells on progression of experimental humanderived tumors in more detail and to learn more about molecular mechanisms underlying a decrease of metastatic activity of cancer cells with downregulated expression of VEGF-C, we created sublines of VEGFR3-positive lung carcinoma A549 and colon carcinoma HCT116 cells with stable repression of VEGF-C production. Analysis of these sublines revealed the complex effect of VEGF-C downregulation on growth and metastasis of subcutaneous and orthotopic tumor xenografts in addition to inhibition of cell proliferation, migration and tumor lymphangiogenesis described previously; we also observed novel effects, that is, partial reversion of epithelial-mesenchymal transition (EMT) and a decrease in the percentage of tumor-initiating cells, also known as 'cancer stem cells' (CSCs). These results indicate high potentiality of VEGF-C as a cancer drug target.
Results
To reveal both autocrine and paracrine effects of inhibition of VEGF-C production on tumor progression, we introduced lentiviral constructs carrying shVEGFCs homologous to different parts of VEGF-C gene (Materials and methods) into VEGFR3-positive human lung carcinoma A549 and colon carcinoma HCT116 cells. Transduction of shVEGFC-3 or shVEGFC-5 resulted in a stable decrease of VEGF-C mRNA expression and protein content that was observed both in cell cultures in vitro (Figures 1a and b ) and in their xenografts in nude mice ( Figure 1c) . In all created sublines of A549 and HCT116 cells, downregulation of VEGF-C expression caused a significant reduction in growth rate that was observed not only in cell cultures in vitro (Supplementary Figure S1 ), but also in their subcutaneous xenografts in nude mice (Figure 2) . Moreover, using the model of ortothopic xenografts of A549 cells in the middle lobe of the right lung, we have found that VEGF-C downregulation was accompanied by about twofold decrease in the number of metastasis in other lung lobes (Figure 3) .
To assess the possible impact of various effects of VEGF-C downregulation on metastasis, we studied changes in blood and lymphatic vessel density in primary tumors and surrounding normal tissues (that is, paracrine effects) and invasive activity of cancer cells in vitro (that is, autocrine effects). Inhibition of VEGF-C production in both A549 and HCT116 tumor xenografts did not cause significant changes in the blood microvessel density as detected by counting CD34-positive structures (Supplementary Figure S2) . On the other hand, the density of LYVE-1-positive structures probably representing lymphatic vessels was substantially decreased in subcutaneous and lung A549 tumor xenografts with downregulated VEGF-C (Figure 4 ). In addition, inhibition of VEGF-C expression led to some decrease in the density of lymphatic structures in peritumoral lung tissues (Figure 4b) .
To test the changes in cell migration ability and invasive activity in vitro, Boyden chamber assay using uncoated and matrigel-coated filters was performed. The ability of cells to migrate into wound in vitro was also studied. All tests showed prominent decrease of migration ability of A549 and HCT116 cells with downregulated VEGF-C ( Figure 5 ). Noteworthy, the migration through matrigel-coated filters was inhibited to a greater extent than migration through uncoated filters (Figure 5a ).
To learn more about the mechanisms underlying the alterations in cell migration, we studied whether the cells with inhibited VEGF-C expression showed changes in manifestation of some features of EMT, a basic determinant of increased migration activity of cancer cells (reviewed in Polyak and Weinberg (2009) ; Thiery et al. (2009) ). We found that VEGF-C downregulation was accompanied by reappearance of certain traits of epithelial phenotype and a decrease in expression of mesenchymal markers that was observed in both A549 ( Figure 6 ) and HCT116 cells (Supplementary Immature forms of VEGF-C bind only to VEGFR3; mature form binds to VEGFR3 with higher affinity than immature forms, and additionally interacts with VEGFR2 (Joukov et al., 1997) . a-tubulin protein was analyzed as loading control. (c) Immunohistochemical analysis of VEGF-C expression in tumor xenografts. Formalin-fixed sections from tumors formed 3-6 weeks after injection of HCT116 and A549 cells, respectively, were stained with anti-VEGF-C antibody. Typical fields of view are presented.
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N Khromova et al Figure S3 ). In fact, VEGF-C low cells showed an increase in expression of a set of cytokeratins including cytokeratin-8, a decrease in expression of vimentin, more pronounced E-cadherin-containing adherence junctions and a decrease in expression of N-cadherin. It should be stressed that such changes were observed both in cell cultures in vitro ( Figure 6a ) and tumor xenografts in vivo (Figure 6b ; Supplementary Figure S3 ).
EMT in cancer cells is accompanied by appearance of traits of so-called CSCs, which are considered key players in development of metastasis (Mani et al., 2008; Gupta et al., 2009; Polyak and Weinberg, 2009; Singh and Settleman, 2010) . To determine whether VEGF-C downregulation affects the percentage of cells with the CSC traits in A549 and HCT116 cell populations, we used three commonly accepted approaches: (i) determined the cell dose threshold for tumor formation in nude mice; (ii) assessed colony formation in semisolid medium; and (iii) detected cells that effectively exclude Rhodamine 123-and/or Hoechst 33342 (Wu and Alman, 2008; Singh and Settleman, 2010) . All three tests showed that VEGF-C downregulation was accompanied by a decrease in number of cells with features attributed to CSCs. In fact, tumorigenic dosage for VEGF-C low A549 and HCT116 derivatives substantially increased ( Table 1) 
Discussion
Our results show that downregulation of VEGF-C production in lung and colon cancer cells expressing its receptor VEGFR3 leads to significant inhibition of tumor growth and metastasis. This effect is probably 6 cells in the middle lobe of right lung and the number of metastases was counted in all lung lobes, except a middle lobe in which the primary tumor was located. Each experimental group contained 10 mice; in each case, for each lung lobe at least 10 sections were analyzed; the experiment was repeated twice with similar result. (a) A549 metastases 5 weeks after injection are pointed with arrows (H&E, magnification Â 100-left, Â 400-right; typical fields of view are presented). (b) Quantitative presentation of metastatic activity of A549 cells with downregulated VEGF-C. The result of one of the experiments is presented; the difference in the number of lung metastases in mice bearing control (shGFP) tumors and those with downregulated VEGF-C was significant according to Student's t-test (*Po0.05).
Downregulation of VEGF-C expression N Khromova et al due to multiple consequences of the attenuation of autocrine and paracrine VEGF-C signaling. Several of these effects were described earlier and confirmed in our study. In fact, similar to other investigators (Su et al., 2006; Timoshenko et al., 2007; Kodama et al., 2008; Chen et al., 2010) , we observed that in vitro cancer cells with downregulated VEGF-C show reduced proliferation and/or migration. Using in vivo analysis, which allows to reveal not only autocrine but also paracrine effects, we found that in addition to deceleration of tumor growth, VEGF-C downregulation caused inhibition of lymphangiogenesis in tumor and surrounding tissues. To assess an influence of these effects on metastatic activity of cancer cells, we used a model of A549 orthotopic lung xenograft, capable to form metastasis in other lung lobes (Wang et al., 1992; Yamaura et al., 2000) . We found that the number of lung metastasis in animals bearing A549 xenografts with inhibited VEGF-C expression was reduced about twofold.
In addition to effects of VEGF-C downregulation mentioned above, we found for the first time that it also caused changes in differentiation state of carcinoma cells in vitro and in vivo. In particular, both A549 and HCT116 cells showed a partial reversion of EMT, which is considered as a major mechanism of carcinoma cell migration (Guarino et al., 2007; Hugo et al., 2007; Polyak and Weinberg, 2009; Thiery et al., 2009) . In fact, inhibition of VEGF-C production caused a suppression of vimentin and N-cadherin expression and induction of cytokeratins and E-cadherin expression, that is, changed the expression of a set of markers that are commonly used for detection of EMT (reviewed in Zeisberg and Neilson, 2009) . This result provides a new insight into the basic mechanisms underlying the increased migration ability of carcinoma cells with activated VEGF-C/ VEGFR3 axis: it is evident that the consequences of this signaling are not restricted to the activation of separate pathways such as VEGFR3-Src-p38 MAPK-C/EBPcontactin1 pathway described earlier (Su et al., 2006) , but reflect more global alterations in cell differentiation programs including those responsible for acquisition of a fibroblast-like morphology and increased cell motility.
Taking into consideration the overlapping characteristics of cells undergoing EMT and cells with the Nude mice assay showed that a significantly higher number of cells from VEGF-C low cell cultures had to be injected to form a tumor. This finding indicates that VEGF-C downregulation decreases the percentage of cells possessing tumor-initiating ability, a basic feature of CSCs. Two additional tests, colony formation in semisolid medium and drug efflux assay, which detects CSC-associated increased ability to exclude the drugs transported by ABC-cassette proteins (reviewed in Wu and Alman, 2008) , confirmed the influence of VEGF-C production on the features ascribed to CSCs. Reduction of the percentage of cells showing multidrug resistance following VEGF-C downregulation opens another possibility for the usage of VEGF-C targeting, that is, prevention of appearance of drug-resistant clones.
Signaling pathways responsible for VEGF-C-dependent EMT and acquisition of features of CSCs remain to be identified. It was established that in lymphatic endothelial cells VEGF-C/VEGFR3 axis regulates a large set of signaling molecules, such as Erk1/2, Akt, Stat3,5, PI3K, and so on (reviewed in Bahram and Claesson-Welsh, 2010) , whose activation can contribute to EMT. mRNA and protein profiling of subsets of cancer cells differing in expression of VEGF-C and in the features of EMT and CSCs followed by further analysis of a possible role of differentially expressed proteins can help to answer this question.
Taken together, our results demonstrate that downregulation of VEGF-C in cancer cells expressing its receptor VEGFR3 inhibits tumor growth and metastasis via multiple effects targeting basal features of neoplastic cells. These effects include (i) attenuation of paracrine regulation of lymphangiogenesis that evidently decreases tumor drainage and spread of cancer cells and (ii) inhibition of autocrine regulation, which is responsible for stimulation of proliferation of cancer cells and acquisition of a fibroblast-like morphology, an increased motility and features of CSCs, that is, enhanced tumor-initiating ability and increased drug resistance. It is evident that VEGF-C is an attractive target for the development of new anticancer strategies.
Materials and methods

Cells
Human colon carcinoma HCT116 cell line (ATCC # CCL-247) and human lung carcinoma A549 cell line (ATCC #CCL-185) expressing VEGFR3 (Su et al., 2006; Khromova et al., 2009) were used. For expression of siRNAs specific for VEGFC, the hairpin structures containing the 5 0 -CCAACCGAGAATTTG ATGAAA-3 0 (shVEGF-C#3) and 5 0 -CAAACCAGTAACAA TCAGTTT-3 0 (shVEGF-C#5) 21-bp sequences corresponding to two different parts of VEGF-C mRNA were synthesized (Evrogen, Moscow, Russia) and cloned into the lentiviral pLKO.1-puro vector (Sigma-Aldrich, St Louis, MO, USA). The lentiviral gene transfer and selection of recipient cultures was performed as described earlier (Khromova et al., 2009) . Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin/ streptomycin. All the experiments were performed 7-30 days after lentiviral vector-mediated gene transfer.
Detection of VEGF-C mRNAs by RT-PCR
Total mRNA was isolated with SV Total RNA Isolation System (Promega, Madison, WI, USA). RT-PCR analysis was performed as described (Khromova et al., 2009 ). To 
Western analysis
Whole cell extracts were lysed in ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% deoxycholate Na, 1% NP-40, 0.1% SDS, 100 mM phenylmethylsulfonyl fluoride, 1 mM pepstatin A and 1 mM E64). Protein concentration in the extracts was determined with a protein assay system (BioRad Laboratories, Hercules, CA, USA). In all, 20 mg of protein was separated on a 12% SDS polyacrylamide gel and transferred to a polyvinylidene difluoride membrane (Amersham GE Healthcare, Piscataway, NJ, USA). The membranes were probed with antibodies specific to VEGF-C (34-5500, Invitrogen, Carlsbad, CA, USA) and a-tubulin (sc-23948, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were treated with secondary anti-mouse/rabbit-HPR (Amersham GE Healthcare). Filters were developed with enhanced chemiluminescence reagents (Amersham GE Healthcare) according to the manufacturer's protocol.
Immunofluorescent microscopy Cells were plated on SlideFlask (NUNCLON), infected with lentiviral constructs, grown without passaging and fixed on the seventh day with methanol/acetone, incubated with anti-Ecadherin (205602, Calbiochem, Darmstadt, Germany), N-cadherin (M3613, DAKO, Glostrup, Denmark), vimentin (M0725, DAKO), cytokeratin 8 (sc-8020, Santa Cruz Biotechnology) primary antibodies for 1 h at room temperature and detected with Alexa488-conjugated secondary antibody (Invitrogen) for 30 min at room temperature. The SlideFlask were mounted with cover slips and images were acquired using fluorescent Axioplan 2 microscope and AxioVision (Carl Zeiss MicroImaging GmbH, Goettingen, Germany) software. Statistical analysis of fluorescence intensity of obtained images was performed using ImageJ (Wayne Rasband, NIH, UK) software. At least 50 fields in three independent experiments ware calculated.
FACScan analysis
Cells were collected from subconfluent culture by trypsinization and resuspended at 10 6 cells/ml in pre-warmed Hank's balanced salt solution containing 2% fetal bovine serum. Then, the cells were incubated with 1 mg/ml Rhodamine123 dye (R8004, Sigma) for 30 min in dark at 37 1C with intermittent mixing. At the end of the incubation, cells were spun down and washed in cold Hank's balanced salt solution containing 2% fetal bovine serum at 4 1C and were labeled with 10 mg/ml propidium iodide (P4170, Sigma) to distinguish live from dead cells before analysis. Rhodamine123 staining was detected using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA), exciting at 488 nm and detecting Rhodamine123 with a 530/30 broad pass (BP) filter and propidium iodide with a 630/22 BP filter. Every time we collected 10 7 events within the live gate for further analysis using BD FACSDiva Software (BD Biosciences) and WinMDI (by Joseph Trotter, La Jolla, CA, USA) software. Boyden chamber cell migration assay Boyden chamber cell migration assay was performed using transwell uncoated and matrigel-coated chambers with 8 mm pore-size membranes (BD Biosciences). The chambers were inserted into 24-well culture plates containing Dulbecco's modified Eagle's medium with 10% fetal bovine serum. The cells (5 Â 10 4 for A549 and 2.5 Â 10 4 for HCT116) were loaded into the upper volume of the Boyden chambers. In 24 h, nonmigrated cells were removed with a cotton swab and the cells were fixed with methanol for 15 min and stained with crystal violet. The migration activity was quantified by blind counting of the migrated cells on the lower surface of the membrane of at least 10 fields per chamber using a Â 20 objective.
Wound healing cell migration assay Wounds were done on confluent A549 and HCT116 cell cultures by the pipette tip. To estimate cell migration the culture was stained by DAPI 24 h after wounding. The number of nuclei of the cells migrated into the wound was counted in 10 fields of vision at Â 100 magnification.
Nude mice assay
Female D2 Â J nude mice (10 animals for each experimental group) were inoculated subcutaneously into the dorsal flank with 10 6 cells suspended in 100 ml of PBS. Tumor sizes were measured every 3 days and their volumes were calculated as (width 2 ) Â (length) Â 0.5. After 3-6 weeks of observation, explanted tumors were isolated and analyzed immunohistochemically.
Before mice were inoculated intrapulmonary with 10 6 cells suspended in 20 ml of PBS, the needle of the insulin syringe was supplied with a silicon overrun limiter 5 mm from its spike to prevent overpenetration. Injection was performed across the chest, from the right side, in the apex point of the costoclavicular perpendicular curve. After 5-6 weeks of observation, dissection was performed and lungs were removed and fixed in paraformaldehyde for the further histologic analysis. These experiments were repeated at least twice to confirm the results.
The animal experimental protocols were approved by the Committee for Ethics of Animal Experimentation and the experiments were conducted in accordance with the Guidelines for Animal Experiments in Blokhin Memorial Russian Cancer Research Center.
Immunohistochemistry
Tumor tissue was excised from killed mice, rinsed in icecold PBS, fixed in 4% paraformaldehyde for 24 h and embedded in paraffin. Serial 5-mm sections were used for Downregulation of VEGF-C expression N Khromova et al immunohistochemical detection of VEGF-C, CD34, LYVE-1, E-cadherin and N-cadherin. Antigen retrieval was achieved by heating (95 1C) the sections in 0.01 M citrate buffer, pH 6.0 (for VEGF-C, CD34 and E-/N-cadherins) for 40 min or proteinase K (for LYVE-1) for 5 min at room temperature. The slides with primary antibodies specific to VEGF-C (34-5500, Invitrogen), CD34 (553731, BD Biosciences Pharmingen, San Diego, CA, USA), LYVE-1 (103-PA50S, RELIATech GmbH, Wolfenbu¨ttel, Germany), E-cadherin (205602, Calbiochem) and N-cadherin (M3613, DAKO) were incubated overnight at 4 1C. Sections were incubated for 30 min at room temperature with anti-rabbit/mouse horseradish peroxidase (Envision, DAKO) to identify the target; the peroxidase reactivity was visualized with 3,3 0 -diaminobenzidine (DAB þ , DAKO) according to the manufacturer's instructions. Sections were counterstained with Mayer's hematoxylin and mounted. Statistics for the intensity of immunohistochemistry dyeing was calculated using ImageJ software. For each cell type the sections from 10 tumors were studied, in each section at least 10 fields of vision were analyzed. In total, for each cell type at least 100 fields of vision were studied.
Lymphatic vessels count
Lymphatic vessel density in subcutaneous tumors was analyzed by counting all LYVE-1-stained vessels at Â 200 magnification. On average, immunohistochemistry quantification was performed by taking pictures from maximum possible fields per tumor; each experimental group contained 16-20 tumors. Intratumoral lymphatic vessel density and peritumoral lymphatic vessel density (lymphatics that were located at periphery tissue within 2 mm of primary tumor adjacent to the invasive front) were analyzed separately. Quantification of LYVE-1-positive structures was performed by taking pictures from 8-12 fields per tumor/lung.
Lung metastases count
Lung metastases count was performed on 10 serial sections of lung stained with hematoxylin and eosin at Â 100 magnification. Metastases were counted in all lobes of a lung, except a middle lobe in which the primary tumor was located.
